Patent Assignment
Reel/Frame 062155/0043
Merger
Recorded: 2022-12-20
Pages: 6
Assignor
ATAXION, INC.
Executed: 2017-03-03
Assignee
LUC THERAPEUTICS, INC.
400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE, MASSACHUSETTS, 02139
Covered Properties
(4)
Potassium Channel Modulating Agents and Their Medical Use
Purinyl Derivatives and Their Use as Potassium Channel Modulators
Substituted [1,2,4]Triazolo[1,5-a]Pyrimidines and Their Use as Potassium Channel Modulators
Purinyl Derivatives and Their Use as Potassium Channel Modulators
Related Assignments
(11)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Oct 2, 2007
From: ERIKSEN, BIRGITTE L.; TEUBER, LENE; HOUGAARD, CHARLOTTE; SORENSEN, ULRIK SVANE
To: NEUROSEARCH A/S
Reel/Frame 019905/0260 →
Assignment of Assignor's Interest
Jan 29, 2010
From: ERIKSEN, BIRGITTE L.; SORENSEN, ULRIK SVANE; HOUGAARD, CHARLOTTE; PETERS, DAN
To: NEUROSEARCH A/S
Reel/Frame 023869/0554 →
Assignment of Assignor's Interest
Dec 12, 2011
From: SORENSEN, ULRIK SVANE; ERIKSEN, BIRGITTE L.; HOUGAARD, CHARLOTTE; STROBAEK, DORTE
To: NEUROSEARCH A/S
Reel/Frame 027363/0508 →
Assignment of Assignor's Interest
Mar 4, 2013
From: ERIKSEN, BIRGITTE L; SORENSEN, ULRIK; HOUGAARD, CHARLOTTE; PETERS, DAN
To: NEUROSEARCH A/S
Reel/Frame 029917/0830 →
Assignment of Assignor's Interest
Mar 20, 2013
From: NEUROSEARCH A/S
To: ANIONA APS
Reel/Frame 030049/0894 →
Assignment of Assignor's Interest
Aug 6, 2013
From: ANIONA APS
To: ATAXION, INC.
Reel/Frame 030946/0329 →
Change of Name
Jan 3, 2023
From: LUC THERAPEUTICS, INC.
To: CADENT THERAPEUTICS, INC.
Reel/Frame 062265/0889 →
Assignment of Assignor's Interest
Jan 10, 2023
From: CADENT THERAPEUTICS, INC.
To: NOVARTIS AG
Reel/Frame 062322/0355 →
Assignment of Assignor's Interest
Jan 10, 2023
From: CADENT THERAPEUTICS, INC.
To: NOVARTIS AG
Reel/Frame 062321/0739 →
Assignment of Assignor's Interest
Jan 10, 2023
From: CADENT THERAPEUTICS, INC.
To: NOVARTIS AG
Reel/Frame 062321/0679 →
Assignment of Assignor's Interest
Jan 10, 2023
From: CADENT THERAPEUTICS, INC.
To: NOVARTIS AG
Reel/Frame 062321/0641 →